Associated Papers
Clinical and genomic features of Lynch syndrome differ by tumor site and disease spectrum.
Li S et al.
Nature Communications, 2025
Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors.
Masucci MT et al.
International Journal of Molecular Sciences, 2023
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations.
Villani A et al.
Nature Cancer, 2023
A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib.
Wong NACS et al.
Cancer Genetics, 2022
Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon.
Incorvaia L et al.
Cancers, 2021
Update on Molecular Genetics of Gastrointestinal Stromal Tumors.
Brčić I et al.
Diagnostics (basel, Switzerland), 2021
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs).
Incorvaia L et al.
Therapeutic Advances in Medical Oncology, 2021
Development and validation of a targeted gene sequencing panel for application to disparate cancers.
McCabe MJ et al.
Scientific Reports, 2019
Clinical utility of custom-designed NGS panel testing in pediatric tumors.
Surrey LF et al.
Genome Medicine, 2019
Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples.
Williams HL et al.
Virchows Archiv : an International Journal of Pathology, 2018
Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation.
Klempner SJ et al.
Lung Cancer (amsterdam, Netherlands), 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
Hovelson DH et al.
Neoplasia (new York, N.y.), 2015
High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Künstlinger H et al.
Human Pathology, 2014
Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.
Heinrich MC et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Greater omentum gastrointestinal stromal tumor with PDGFRA-mutation and hemoperitoneum.
Murayama Y et al.
World Journal of Gastrointestinal Oncology, 2012
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
Corless CL et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2005